A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer
- Each treatment cycle lasts 21 days and patients will participate in a least 4 cycles,
but no more than 6 cycles of treatment.
- Patients will receive cytoxan (cyclophosphamide) and epirubicin intravenously on day 1
of each treatment cycle. On days 4-17 of each cycle, patients will take capecitabine
orally twice a day.
- While on the study patients will be required to complete a diary of they capecitabine
- Blood tests will be performed each week along with surveys at the beginning of the
trial and certain follow-up visits to evaluate the patient's experience with the oral
- Patients will be on the treatment for 12-18 weeks depending upon whether or not the
disease progresses or the patient develops inacceptable side effects.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the feasibility of administering cytoxan, epirubicin, and capecitabine to women with Stage I/II/IIIA breast cancer.
Craig Bunnell, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|Dana-Farber Cancer Center||Boston, Massachusetts 02115|